Multiple myeloma diagnostics and monitoring company Sebia, has launched its new serum-based Minimal Residual Disease (MRD) test for monitoring in multiple myeloma. M-inSight is a laboratory developed test being offered by Corgenix (pictured) - a licensed clinical laboratory and part of the Sebia Group.
M-inSight is a personalised, targeted mass spectrometry assay, to detect with unprecedented sensitivity the monoclonal protein (M-protein) secreted by the patient’s tumour cells in serum. The technology is based on clonotypic peptides mass spectrometry, which avoids the interference with the polyclonal background leading to an ultra-sensitive test.
MRD describes the low levels of myeloma cells that persist in the bone marrow after treatment but cannot be detected with conventional outcome measures and eventually lead to relapse. MRD status is an important prognostic marker and studies have shown its potential as a surrogate endpoint for progression-free survival. MRD testing monitors the effectiveness of a treatment and could be a driver in treatment decisions.
As new therapies emerge to treat patients suffering from multiple myeloma, there is an urgent need for high sensitivity MRD testing in serum to track disease burden and treatment efficacy, without the limitations of current bone marrow-based assays. These are typically invasive, painful and not suited for frequent measurement. M-inSight was developed in partnership with Erasmus Medical Center, Rotterdam, and Radboud University Medical Center, Nijmegen, both in the Netherlands.
“We are proud to launch M-inSight to improve the management of multiple myeloma and quality of life for patients, as well as assisting in the drug development and validation process”, said Dr Pierre Sonigo, Chief Scientific Officer at Sebia. “By testing in serum with equivalent sensitivity to bone marrow, we will solve current challenges in multiple myeloma MRD-testing, allowing for a more frequent and reliable monitoring of response to treatment.”
